<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<!-- saved from url=(0121)http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?f=templates&fn=document-frame.htm&2.0 -->
<HTML><HEAD><TITLE>Clinical Evidence</TITLE>
<META content="text/html; charset=iso-8859-1" http-equiv=Content-Type><LINK 
href="0205_i16_files/bmj.css" rel=stylesheet type=text/css>
<META content="MSHTML 5.00.3103.1000" name=GENERATOR>
</HEAD>
<BODY topMargin=0>
<TABLE border=1 borderColorDark=#ffffff borderColorLight=#c2c2c2 cellPadding=0 
cellSpacing=0 width="100%">
  <TBODY>
  <TR>
    <TD class=heading id=heading>
      <SCRIPT src="0205_i16_files/0205_i16.0"></SCRIPT>

      <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>

      <TABLE border=0 width="100%">
        <TBODY>
        <TR>
          <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular 
            disorders</SECTION></SPAN><IMG align=absMiddle border=0 height=10 
            src="0205_i16_files/spacer.gif" width=10><BR><SPAN class=localhead 
            id=localhead><TOPIC>Primary prevention</TOPIC><IMG align=absMiddle 
            border=0 height=10 src="0205_i16_files/spacer.gif" 
          width=10></SPAN></TD></TR>
        <TR>
          <TD align=right bgColor=#ffffff class=title-author height=30 
          id=title-author noWrap vAlign=top>Clinical Evidence writers on primary 
            prevention<IMG align=absMiddle 
            border=0 height=10 src="0205_i16_files/spacer.gif" 
        width=10></TD>
        </TR></TBODY></TABLE><BR>
      <H1 
      style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Antihypertensive 
      drugs</H1>
      <TABLE border=0 cellPadding=3 cellSpacing=0 width="100%">
        <TBODY>
        <TR>
          <TD class=question id=question vAlign=top width="10%"><B><SPAN 
            class=question-title id=question-title>QUESTION</SPAN></B></TD>
          <TD class=question id=question>&nbsp;<B>What are the effects of drug 
            treatment in primary hypertension?</B></TD></TR></TBODY></TABLE><BR><A 
      name=I16>
      <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Comparing 
      antihypertensives</H2>
      <TABLE border=0 cellPadding=0 cellSpacing=0 width="100%">
        <TBODY>
        <TR class=option id=option>
          <TD class=option id=option style="PADDING-LEFT: 2px" vAlign=top 
          width="10%"><SPAN class=option-title 
            id=option-title>OPTION&nbsp;&nbsp;&nbsp;</SPAN></TD>
          <TD class=option id=option style="PADDING-LEFT: 2px" 
            width="100%"><B>Comparing antihypertensive drug 
        treatments</B></TD></TR></TBODY></TABLE></A>
      <TABLE border=0 cellPadding=0 cellSpacing=0 width="100%">
        <TBODY>
        <TR>
          <TD><A name=I16-SUMSTATEMENT><B>
            <P align=justify style="MARGIN-LEFT: 3px"><IMG 
            alt="substantive change" border=0 
            src="0205_i16_files/smalrght.gif">Two systematic reviews have found 
              that initial treatment with diuretics, ACE inhibitors, or ß blockers 
              reduces mortality and morbidity, with minimal adverse effects. RCTs 
              found no significant morbidity or mortality differences among these 
              agents. We found limited evidence from one systematic review of 
              RCTs that diuretics, ß blockers, and ACE inhibitors reduced coronary 
              heart disease and heart failure more than calcium channel antagonists. 
              One RCT has found that a thiazide diuretic is superior to an &#945; 
              blocker in reducing cardiovascular events, particularly congestive 
              heart failure.<IMG 
            alt="substantive change" border=0 
            src="0205_i16_files/smalleft.gif"></P>
            </B></A></TD></TR></TBODY></TABLE><BR>
      <TABLE border=0 cellPadding=3 cellSpacing=0 width="100%">
        <TBODY>
        <TR>
          <TD> 
            <P align=justify><FONT color=#0033cc><A 
            name=I16-BENEFITS><B>Benefits: </B></A></FONT><B>ß Blockers versus 
              diuretics: </B>One systematic review (search date 1995, &gt;&nbsp;48&nbsp;000 
              people) identified RCTs comparing effects of high and low dose diuretics 
              versus ß blockers. <A 
            href="#references">[128]</A> A second systematic review (search date 
              1998) was limited to 10 RCTs in 16&nbsp;164 elderly people. <A 
            href="#references">[129]</A> These reviews did not summarise direct 
              comparisons of diuretics versus ß blockers but compared results 
              of trials that used diuretics as first line agents versus results 
              of trials that used ß blockers as first line agents. The reviews 
              found no significant difference between diuretics and ß blockers 
              for lowering blood pressure. They found that diuretics reduced coronary 
              events, but found no evidence that ß blockers reduced coronary events. 
              <B>ß Blockers versus ACE inhibitors: </B>One single blind RCT (10&nbsp;985 
              people, aged 25&#8211;66 years) found that an ACE inhibitor (captopril) 
              was no more effective than conventional treatment (diuretics or 
              ß blockers) in reducing cardiovascular morbidity or mortality. Captopril 
              increased the risk of stroke compared with ß blockers (125 people 
              would need to be treated with ACE inhibitor rather than ß blocker 
              for one extra stroke to occur, 95% CI 69 to 651 people). However, 
              the methods of the trial may limit the validity of results (see 
              comment below). <A 
            href="#references">[130]</A> <B>Comparison of ß blockers, diuretics, 
              ACE inhibitors, and calcium channel antagonists: </B>One unblinded 
              RCT (6600 people, aged 70&#8211;84 years) compared diuretics, ß 
              blockers, or both, versus calcium channel antagonists (felodipine 
              or isradipine) versus ACE inhibitors (enalapril or lisinopril). 
              It found no significant difference in blood pressure control or 
              cardiovascular morbidity or mortality. <A 
            href="#references">[131]</A> <IMG 
            alt="substantive change" border=0 
            src="0205_i16_files/smalrght.gif">One systematic review (search date 
              2000, 8 RCTs) compared different antihypertensive regimens, and 
              found no significant differences in outcome among people initially 
              treated with ß blockers, diuretics, or ACE inhibitors. <A 
            href="#references">[132]</A> However, it found that ß blockers or 
              diuretics decreased coronary events compared with calcium channel 
              antagonists, and increased stroke rate, although there was no significant 
              difference for all cause mortality (OR for mortality, ß blockers 
              or diuretics <EM>v</EM> calcium antagonists 1.01, 95% CI 0.92 to 
              1.11). ACE inhibitors did not significantly alter all cause mortality 
              or stroke rate compared with calcium channel antagonists, but decreased 
              coronary events (OR for ACE inhibitor <EM>v</EM> calcium antagonist 
              1.03, 95% CI 0.91 to 1.18 for all cause mortality; 1.02, 95% CI 
              0.85 to 1.21 for stroke; 0.81, 95% CI 0.68 to 0.97 for coronary 
              events). <A 
            href="#references">[132]</A> <IMG 
            alt="substantive change" border=0 
            src="0205_i16_files/smalleft.gif"><B> <font color="#D50000">Comparison 
              of &#945; blockers and diuretics:</font></B><font color="#D50000"> 
              A double blind RCT (335 high risk people with hypertension) found 
              no differences in coronary heart disease outcomes between doxazosin, 
              an &#945; blocker, compared with chlorthalidone. However, doxazosin 
              compared with chlorthalidone increased the total number of cardiovascular 
              events (4 year rate 25% <EM>v</EM> 22%; HR 1.25, 95% CI 1.17 to 
              1.33) and, in particular, increased congestive heart failure (4 
              year rate 8% <EM>v</EM> 4%; HR 2.04, 95% CI 1.79 to 2.32).</font> 
              <A 
            href="#references">[133]</A> <B>Drug treatment in people with diabetes: 
              </B>See cardiovascular disease in diabetes.</P>
          </TD></TR></TBODY></TABLE>
      <TABLE border=0 cellPadding=3 cellSpacing=0 width="100%">
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I16-HARMS><B>Harms: </B></A></FONT><B>Quality 
              of life and tolerability:</B> In the three long term, double blind 
              comparisons of low dose diuretics, ß blockers, ACE inhibitors, and 
              calcium channel blockers, tolerability and overall quality of life 
              indicators tended to be more favourable for diuretics and ß blockers 
              than for newer drugs. <A 
            href="#references">[134]</A> <A 
            href="#references">[135]</A> <A 
            href="#references">[136]</A> One systematic review (search date 1998) 
              of RCTs comparing thiazides versus ß blockers found that thiazides 
              were associated with fewer withdrawals because of adverse effects 
              (RR 0.69, 95% CI 0.63 to 0.76). <A 
            href="#references">[137]</A> Adverse effects are agent specific. The 
              recent unblinded RCT comparing diuretics, ß blockers, calcium channel 
              antagonists, and ACE inhibitors found that after 5 years of follow 
              up, 26% of people receiving felodipine or isradipine reported ankle 
              oedema, 30% receiving enalapril or lisonopril reported cough, and 
              9% receiving diuretics and/or ß blockers reported cold hands and 
              feet. <A 
            href="#references">[131]</A> <B>Major harm controversies:</B> Case 
              control, cohort, and randomised studies suggest that short and intermediate 
              acting dihydropyridine calcium channel blockers, such as nifedipine 
              and isradipine, may increase cardiovascular morbidity and mortality. 
              <A 
            href="#references">[138]</A> </P>
          </TD></TR></TBODY></TABLE>
      <TABLE border=0 cellPadding=3 cellSpacing=0 width="100%">
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I16-COMMENT><B>Comment: 
              </B></A></FONT>Results of the large ACE inhibitor trial reported 
              above warrant cautious interpretation because a flaw in the randomisation 
              process resulted in unbalanced groups. <A 
            href="#references">[130]</A> </P>
          </TD></TR></TBODY></TABLE><BR><A name=references></A>
      <TABLE border=0 cellPadding=0 cellSpacing=0>
        <TBODY>
        <TR>
          <TD bgColor=#404040 width=90><IMG align=absMiddle border=0 height=2 
            src="" width=1></TD>
          <TD bgColor=#404040 vAlign=bottom width="100%"><IMG align=absMiddle 
            border=0 height=2 src="" width=1></TD></TR>
        <TR>
          <TD bgColor=#404040 class=key-message id=key-message 
            width=90><B>References</B></TD>
          <TD width="100%">&nbsp;</TD></TR></TBODY></TABLE><BR>
      <TABLE align=center cellPadding=2 width="100%">
        <TBODY>
        <TR><A class=reference id=reference name=REF128></a>
          <TD class=reference id=reference vAlign=top width=15>128. </TD>
          <TD class=reference id=reference vAlign=top width="100%"><a href="../../Original%20papers/Alpha%20Blocker%20Monotherapy%20text.html#Wright">Psaty 
            BM, Smith NS, Siscovick DS, et al. Health outcomes associated with 
            antihypertensive therapies used as first line agents: a systematic 
            review and meta-analysis. <EM>JAMA</EM> 1997;277:739&#8211;745. Search 
            date 1995; primary source Medline.</a></TD>
        </TR>
        <TR><A class=reference id=reference name=REF129></a>
          <TD class=reference id=reference vAlign=top width=15>129. </TD>
          <TD class=reference id=reference vAlign=top width="100%"> Messerli FH, 
            Grossman E, Goldbourt. Are beta blockers efficacious as first-line 
            therapy for hypertension in the elderly? A systematic review. <EM>JAMA</EM> 
            1998;279:1903&#8211;1907. Search date 1998; primary source Medline.</TD>
        </TR>
        <TR><A class=reference id=reference name=REF130></a>
          <TD class=reference id=reference vAlign=top width=15>130. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Hansson L, 
            Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme 
            inhibition compared with conventional therapy on cardiovascular morbidity 
            and mortality in hypertension: the captopril prevention project (CAPP) 
            randomised trial. <EM>Lancet</EM> 1999;353:611&#8211;616. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF131></a>
          <TD class=reference id=reference vAlign=top width=15>131. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Hansson L, 
            Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive 
            drugs in elderly patients: cardiovascular mortality and morbidity 
            the Swedish trial in old patients with hypertension-2 study. <EM>Lancet</EM> 
            1999;354:1751&#8211;1756. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF132></a>
          <TD class=reference id=reference vAlign=top width=15>132. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Blood Pressure 
            Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, 
            calcium antagonists, and other blood-pressure-lowering drugs: results 
            of prospectively designed overviews of trials. <EM>Lancet</EM> 2000;356:1955&#8211;1964. 
            Search date July 2000; primary sources WHO-International Society of 
            Hypertension registry of randomised trials; trials were sought that 
            had not published or presented their results before July 1995.</TD>
        </TR>
        <TR><A class=reference id=reference name=REF133></a>
          <TD class=reference id=reference vAlign=top width=15>133. </TD>
          <TD class=reference id=reference vAlign=top width="100%">The ALLHAT 
            Officers and Coordinators for the ALLHAT Collaborative Research Group. 
            Major cardiovascular events in hypertensive patients randomized to 
            doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering 
            treatment to prevent heart attack trial (ALLHAT). <EM>JAMA</EM> 2000;283:1967&#8211;1975. 
          </TD>
        </TR>
        <TR><A class=reference id=reference name=REF134></a>
          <TD class=reference id=reference vAlign=top width=15>134. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Neaton JD, 
            Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study: 
            final results. <EM>JAMA</EM> 1993;270:713&#8211;724. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF135></a>
          <TD class=reference id=reference vAlign=top width=15>135. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Materson BJ, 
            Reda DJ, Cushman WC, et al. Single drug therapy for hypertension in 
            men. <EM>N Engl J Med</EM> 1993;328:914&#8211;921. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF136></a>
          <TD class=reference id=reference vAlign=top width=15>136. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Philipp T, 
            Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, 
            double blind, multicentre comparison of hydrochlorothiazide, atenolol, 
            nitrendipine, and enalapril in antihypertensive treatment: results 
            of the HANE study. <EM>BMJ</EM> 1997;315:154&#8211;159. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF137></a>
          <TD class=reference id=reference vAlign=top width=15>137. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Wright JM, 
            Lee CH, Chambers CK. Systematic review of antihypertensive therapies: 
            does the evidence assist in choosing a first line drug? <EM>Can Med 
            Assoc J</EM> 1999;161:25&#8211;32. Search date 1998; primary sources 
            Medline 1996 to 1997, Cochrane Library to 1998.</TD>
        </TR>
        <TR><A class=reference id=reference name=REF138></a>
          <TD class=reference id=reference vAlign=top width=15>138. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Cutler JA. 
            Calcium channel blockers for hypertension&nbsp;&#8212;&nbsp;uncertainty 
            continues. <EM>N Engl J Med</EM> 1998;338:679&#8211;680.</TD>
        </TR></TBODY></TABLE>
      <TABLE border=0 width="100%">
        <TBODY>
        <TR>
          <TD vAlign=bottom width="50%">
          <TD align=right width="50%"><IMG 
            alt="BMJ - Clinical Evidence" border=0 
            src="../ce-bmj-small-banner%5B1%5D.gif" width="89" height="44"></TD>
        </TR>
        <TR>
          <TD align=left width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">Issue 5 - June 
          2001</SPAN></TD>
          <TD align=right width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing Group</SPAN></TD>
        </TR></TBODY></TABLE>
      <SCRIPT language=JavaScript>
			var purl = "0205.PDF"; 
</SCRIPT>
      </TD></TR></TBODY></TABLE>
<FORM name=LPHitCountForm><INPUT name=LPHitCount type=hidden value=0> 
</FORM></BODY></HTML>
